Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients;Perfil lipídico, fatores de risco cardiovascular e síndrome metabólica em um grupo de pacientes com AIDS

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 2, 2009, Pages 113-118

  Da Silva, Érika Ferrari Rafael ^a   Bassichetto, Katia Cristina ^b   Lewi, David Salomão ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Secretaria Municipal de Saude de Sao Paulo   (Brazil)

Author keywords

Cardiovascular disease; Highly active antiretroviral therapy; Lipid metabolism disorders; Metabolic syndrome X

Indexed keywords

ATAZANAVIR; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BRAZIL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT DEPARTMENT; PREVALENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; BRAZIL; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; METABOLIC SYNDROME X; RISK FACTORS; SMOKING;

EID: 70350704500     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009000800008     Document Type: Article

References (26)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338: 853-860 (Pubitemid 28135961)
2. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000; 23: 35-43. (Pubitemid 30123263)
3. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis. 2000; 30 (Suppl 2): 135-142 (Pubitemid 32268981)
4. Dube M, Sattler F. Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998; 10: 41-44
5. Sweet DE. Metabolic complications of antiretroviral therapy. Top HIV Med. 2005; 13 (2): 70-74.
6. Currier JS, Havlir DV. Complications of HIV disease and antiretroviral therapy. Top HIV Med. 2005; 13 (1): 16-23.
7. Stein J. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003; 45: 293-304. (Pubitemid 36293025)
8. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res. 2006, 4: 79-85.
9. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Therapeutics. 2006; 13: 248-260 (Pubitemid 44026193)
10. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med. 2005; 352: 48-62. (Pubitemid 40075680)
11. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998; 12, F51-F58. (Pubitemid 28190689)
12. Hajjar LA, Calderaro D, Yu PC, Giuliano I, Lima EMO, Barbaro G, et al. Cardiovascular manifestations in patients with the human immunodeficiency virus. Arq Bras Cardiol. 2005; 85 (5): 365-377 (Pubitemid 43127734)
13. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003; 348: 702-710 (Pubitemid 36237039)
14. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D'Arminio Monforte A, et al. For the D.A.D Study Group. Cardiovascular disease risk factors in HIV patients - associations with antiretroviral therapy: results from the DAD Study. AIDS. 2003; 17: 1179-1193
15. Holmberg SD, Moorman AC, Willianson JM, Tong TC, Ward DJ, Wood KC, et al and the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002; 360: 1747-1748
16. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk for myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003; 17: 2479-2486
17. Currier J, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003; 33: 506-512 (Pubitemid 36886080)
18. Gazzaruso C, Bruno C, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003; 21: 1377-1382 (Pubitemid 36904390)
19. Bruno R, Gazzaruso C, Sacchi P, Zocchetti C, Giordanetti C, Garzaniti A, et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J Acquir Immune Defic Syndr. 2002; 31: 363-365 (Pubitemid 35278640)
20. Estrada V, Martinez-Larrad T, Gonzalez-Sanchez JL, de Villar NGP, Zabena C, Fernandez C, et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism. 2006; 55 (7): 940-945 (Pubitemid 43902897)
21. Dawber TR, Meadors GF, Moore FE Jr. Epidemiolofical approaches to heart disease: the Framingham Study. Am J Public Health. 1951; 41 (3): 279-281
22. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106: 3143-3421
23. Caramelli B, de Bernoche CYSM, Sartori AMC, Sposito AC, Santos RD, Monachini TS, et al. Hyperlipidaemia related to the use of HIV protease inhibitors: natural history and results of treatment with Fenofibrate. Braz J Infect Dis. 2001; 5 (6): 332-338
24. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL. Bucher HC, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006; 7 (6): 404-410 (Pubitemid 44123252)
25. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet. 1998; 351: 1881-1883 (Pubitemid 28279721)
26. Bergensen BM, Sandvik L, Brunn JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004; 23: 625-630 (Pubitemid 39222637)